BioSpace News Archive

Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced another key update regarding its Preecludia preeclampsia rule-out test.

Lumos Diagnostics announced today the expansion of its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business

For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.

Cipher Pharmaceuticals Inc. (TSX:CPH) (“Cipher” or “the Company”) today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. The company will hold a conference call on Friday, May 14, 2021 to discuss the results.

As BioConsortia continues its discovery and development of powerful microbes with unique modes of action and innovates further into gene editing for microbial biopesticides and nitrogen fixation, we are pleased to announce that Nancy Vosnidou will join the BioConsortia team in the newly created position of IP & Portfolio Strategist.

FIGS, Inc. (FIGS), a direct-to-consumer healthcare apparel and lifestyle brand founded by Heather Hasson and Trina Spear, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

CCS Medical, Inc., one of the nation’s leading providers of home medical supplies and services, has named Barbara Escalante Hess as Chief Human Resources Officer.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced ZYNLONTA™

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug Designation (ODD) for sacituzumab govitecan-hziy